EY US unveils Matthew Chang of Chang Robotics as an Entrepreneur Of The Year® 2025 Florida Award finalist
JACKSONVILLE, Fla. , May 15, 2025 (GLOBE NEWSWIRE) -- Ernst & Young LLP (EY US) announced the finalists for the prestigious Entrepreneur Of The Year 2025 Florida Award. Now in its 40th year, the Entrepreneur Of The Year program celebrates the bold leaders who disrupt markets through the world's most ground-breaking companies, revolutionizing industries and making a profound impact on communities. The program honors bold entrepreneurs whose innovations shape the future and pave the way for a thriving economy and a hopeful tomorrow.
An independent panel of judges selected Matthew Chang, Founder of Chang Robotics, among 25 finalists for their entrepreneurial spirit, purpose, growth, and lasting impact in building long-term value.
'I am beyond honored to be included among such tremendous and inspiring leaders as one of this year's regional EY finalists,' said Chang. 'This program is one that I've long admired for its focus on innovation, high achievement and both business and community success. This league of individuals is changing the world.'
Chang Robotics is a DBE-certified engineering firm at the forefront of advanced manufacturing, collaborative robotics, and disruptive automation. Founded in 2017, Chang Robotics has rapidly grown, delivering innovative, data-driven solutions, including some of the world's largest autonomous systems. Recognized as one of Fast Company's 2024 Best Workplaces for Innovators, the company revolutionizes supply chain automation and enhances workforce productivity through human-focused robotics. In 2025 the company has also launched the Chang Robotics Fund, a $50M with a focus on launching and building 15-plus early stage high-innovation companies using the same model and practices that have driven Chang Robotics' iconic success. With a commitment to sustainability and cutting-edge technology, Chang Robotics empowers businesses across manufacturing, government, healthcare, and beyond. To learn more or connect with us, email [email protected], visit www.ChangRobotics.ai, and follow us on LinkedIn.
Entrepreneur Of The Year honors business leaders for their ingenuity, courage and entrepreneurial spirit. The program celebrates original founders who bootstrapped their business from inception or who raised outside capital to grow their company; transformational CEOs who infused innovation into an existing organization to catapult its trajectory; and multigenerational family business leaders who reimagined a legacy business model to strengthen it for the future.
Regional award winners will be announced on June 13 during a special celebration in Orlando and will become lifetime members of an esteemed community of Entrepreneur Of The Year alumni from around the world. The winners will then be considered by the National judges for the Entrepreneur Of The Year National Awards, which will be presented in November at the annual Strategic Growth Forum ®, one of the nation's most prestigious gatherings of high-growth, market-leading companies.
Sponsors
Founded and produced by Ernst & Young LLP, the Entrepreneur Of The Year Awards include presenting sponsors PNC Bank, Cresa, LLC, Marsh USA, and SAP. In Florida, sponsors also include ADP – regional Silver sponsor.
About Entrepreneur Of The Year
Founded in 1986, Entrepreneur Of The Year has celebrated more than 11,000 ambitious visionaries who are leading successful, dynamic businesses in the US, and it has since expanded to nearly 60 countries globally.
The US program consists of 17 regional programs whose panels of independent judges select the regional award winners every June. Those winners compete for national recognition at the Strategic Growth Forum ® in November where National finalists and award winners are announced. The overall National winner represents the US at the EY World Entrepreneur Of The Year™ competition. Visit ey.com/us/eoy.
About EY
EY is building a better working world by creating new value for clients, people, society and the planet, while building trust in capital markets.
Enabled by data, AI and advanced technology, EY teams help clients shape the future with confidence and develop answers for the most pressing issues of today and tomorrow.
EY teams work across a full spectrum of services in assurance, consulting, tax, strategy and transactions. Fueled by sector insights, a globally connected, multi-disciplinary network and diverse ecosystem partners, EY teams can provide services in more than 150 countries and territories.
All in to shape the future with confidence.
EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. Information about how EY collects and uses personal data and a description of the rights individuals have under data protection legislation are available via ey.com/privacy. EY member firms do not practice law where prohibited by local laws. For more information about our organization, please visit ey.com.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/36d1c450-e2d8-4375-bc40-be96899f92b8
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
DSC® Sponsors the 17th Annual Portland Track Festival
DSC® Showcases DREAMCELL®Insoles, Engineered to Fuel Athlete Performance & Recovery PORTLAND, Ore., June 12, 2025 /PRNewswire/ -- DSC®, a global leader in performance foam manufacturing, proudly continues to sponsor the 17th annual Portland Track Festival. As part of its ongoing commitment to athlete-led innovation, DSC® will provide high-performance insoles to athletes at the premiere two-day event. "This year marks 80 years of innovation at DSC®, and we are honored to support the Portland Track Festival once again," said Johnson Chang, CEO of DSC®. "Our mission has always been to design products that meet athletes' highest performance demands. With our ultra-high performance DREAMCELL® and DURAPONTEX® insoles, we're proud to help athletes power through the finish line—and beyond." At the festival, DSC® will provide athletes with DREAMCELL® PX23 and DURAPONTEX® eN25 —two of the DSC's most advanced materials designed to maximize performance, energy return, and comfort. DREAMCELL® PX23 insole is a high-performance insole material under the popular DREAMCELL® brand. Engineered with advanced, high resilience open-cell PU foam, it delivers an unparalleled 50% performance rebound, superior breathability, and long-lasting comfort—supporting athletes through every stride of their journey. DURAPONTEX® eN25 is a next generation, ultra performance closed-cell foam material developed using DSC's proprietary supercritical fluid foaming technology. Engineered specifically for high-impact, jump-dominant sports, it delivers exceptional durability and ultra-lightweight performance. With 65% resiliency, DURAPONTEX® eN25 offers unmatched rebound to support athletes in achieving peak performance. DSC® was the first brand to utilize supercritical foaming technology in the development of an insole at scale with its DURAPONTEX® N-Series. "We appreciate DSC® continuing to support the Portland Track Festival and their commitment to engage with local athletes," said Michael Bergmann, Board Member and Spokesperson of the Portland Track Festival. "These world-class middle and long-distance athletes offer invaluable feedback that helps DSC® refine and elevate its performance products." DSC® not only supports elite athletes at the Portland Track Festival, but also extends nationwide to running clubs across the U.S. Interested running clubs are invited to partner with DSC's Athlete Engagement Program, to test DSC's advanced insole technologies and provide performance data and feedback that drives the next generation of product development. For 80 years since its founding in 1945, Dahsheng Company (DSC®) has been a leader in foam innovation for the sports industries. Known for its premium comfort and performance foam DREAMCELL® and DURAPONTEX®, DSC® partners with top brands and footwear manufacturers worldwide. By advancing innovation and pushing the limits of foam manufacturing, DSC® is dedicated to creating eco-friendly and advanced foam solutions that set new standards in the industry. Visit to learn more about DSC® and its commitment to sustainability and eco-innovation. Media Contact:Erin Pattersont: +1-323-422-0274e: View original content to download multimedia: SOURCE Dahsheng Chemical Sign in to access your portfolio
Business Wire
4 hours ago
- Business Wire
GenSight Biologics Reaches Agreement with ANSM for Opening of LUMEVOQ ® Named Early Access Program (AAC) in France
PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that it has reached agreement with the French medicines safety agency ANSM to consider expeditiously opening the French named early access program (AAC) for LUMEVOQ ® upon approval of a dose-ranging clinical study. Clear Path Forward for LUMEVOQ ® AAC Program in France Following extensive discussions, GenSight reached alignment with ANSM on a plan to open the LUMEVOQ ® AAC program. The agency has agreed that the authorization of a focused dose-ranging study could enable the opening of the early access program. The Company has submitted a preliminary design of the study to the agency and aims to finalize the protocol of a dose-ranging study in Q3 2025. In parallel, the Company will work with the agency to find a solution for patients who may not be included in the study but who may benefit from the AAC program. The AAC program is targeted to open in Q4 2025 at the latest. "In the interest of clearing the way for patients to be treated with LUMEVOQ, we are pleased to have achieved this important agreement with ANSM on a clear path forward for opening patient access to LUMEVOQ in France" said Laurence Rodriguez, Chief Executive Officer of GenSight Biologics."We are thankful for the ANSM's ongoing engagement and openness to discussion, as we work towards the shared goal of providing access to LHON patients who urgently need a safe and effective treatment." Financing Strategy to Support Regulatory Milestones GenSight is implementing a financing strategy to bridge operations through the opening of the AAC program and prepare for the new global Phase III clinical trial. The Company is actively pursuing various funding initiatives to support these critical regulatory milestones. ' We are working on our financing strategy to manage the bridge between now and the opening of the AAC program and the initiation of the Phase III study,' commented Jan Eryk Umiastowski, CFO of GenSight Biologics. "Our focus remains on securing the resources needed to execute our regulatory strategy while exploring additional funding opportunities." Advancing Core Marketing Authorization Strategy In parallel with the French AAC program developments, GenSight will continue to advance its global marketing authorization strategy: Preparation for regulatory consultations in the US and EU Planning for the global Phase III trial scheduled to begin in 2026, designed to meet FDA and EMA requirements Completing the transition to a new manufacturing partner to secure reliable clinical and commercial supply Advancing preparations for MHRA submission in the United Kingdom During this period, the Company will actively pursue additional non-dilutive funding opportunities, including licensing arrangements outside North America and Europe and potential M&A activities. Multiple Value Catalysts GenSight anticipates a number of significant value-creating events in 2025-2026: Financial Position The Company received €0.7 million of its Research Tax Credit (CIR) end of May, with the remaining €0.4 million to be paid in July 2025. Based on current operations and projections, GenSight's cash will support operations until mid-July 2025. The Company acknowledges that current funds are insufficient to cover operational requirements for the next 12 months. The planned financing initiatives are designed to extend the cash runway and enable the initiation of the Phase III clinical trial and UK MHRA marketing application for LUMEVOQ ®. As of June 12, 2025, the number of outstanding GenSight Biologics shares was 131,466,495 ordinary shares. Risk factors Detailed information regarding the Company, including its business, financial information, results, perspectives and related risk factors are contained (i) in the Company's 2024 Universal Registration Document filed with the AMF on April 8, 2025 under number D.25-0234. This document, as well as other regulated information and all of the Company's press releases, can be accessed on the Company's website ( and/or AMF ( The reader's attention is drawn to the risk factors related to the Company and its activities presented in chapter 3 of its 2024 URD in particular the liquidity risk presented in the chapter 3.1.1. About GenSight Biologics GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics' pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics' lead product candidate, GS010 (lenadogene nolparvovec) is in Phase III in Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics' product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery. Forward-Looking Statements This press release contains forward-looking statements, including statements regarding product development prospects and financial projections. These statements do not constitute guarantees of future performance and involve risks and uncertainties. While the Company is actively pursuing financing solutions, regulatory requirements necessitate disclosure that material uncertainty exists regarding the Company's ability to continue as a going concern if sufficient funding cannot be secured. A further list and description of risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements in this press release can be found in GenSight Biologics' regulatory filings with the French Autorité des Marchés Financiers. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, GenSight Biologics undertakes no obligation to update or revise the information contained in this press release.
Yahoo
4 hours ago
- Yahoo
Striim Announces Neon Serverless Postgres Support to Broaden Agentic AI Use Cases with Databricks
PALO ALTO, Calif., June 12, 2025 (GLOBE NEWSWIRE) -- Applications in the AI era depend on real-time data, but data ingestion and integration from legacy architectures often hold them back. Traditional ETL pipelines introduce latency, complexity, and stale intelligence, limiting the effectiveness of LLM-driven applications and Retrieval-Augmented Generation (RAG). For enterprises building on the Postgres stack, bridging that gap between operational data and real-time AI is critical. Open-source Postgres is widely deployed as the back-end database by developers to address operational requirements. Neon builds on this foundation with a new paradigm for the creation of databases by AI agents. Most recently, Databricks announced Lakebase, based on its acquisition of Neon—a fully managed Postgres database that is a popular choice to build AI Applications on. Now, Striim is excited to announce that it is expanding its Postgres offerings with high-throughput ingestion from Neon into Databricks for real-time analytics, as well as high-speed data delivery from legacy systems into Neon for platform and data modernization. Striim's unified platform further allows vector embeddings to be built within the data pipeline while delivering real-time data into Neon and into Databricks for building Agentic AI use cases. Using Striim, developers can seamlessly migrate, integrate, or replicate transactional and event data along with in-flight vector embeddings, enriched context, and cleansed high-quality data from multiple operational stores into Neon. This modern integration allows modern agentic applications to be rapidly built with Neon as the transactional backend. With this added capability, organizations can: Seamlessly replicate operational data in real-time from traditional systems like Oracle, PostgreSQL, MySQL, SQL Server, and hundreds of other sources to Neon, with zero downtime and automated schema evolution. Enable real-time ingestion and Change Data Capture (CDC) from Neon into Databricks, ensuring AI models and analytics workloads always operate on fresh data. Fuel Retrieval-Augmented Generation (RAG) and generative AI use cases natively within Neon or Databricks with inline data enrichment and vector embeddings. Stream event data from Apache Kafka into Neon in real time, eliminating the need for brittle batch-based integrations. Maintain end-to-end data governance with in-flight AI-driven PII detection and resolution, encryption, and support for customer-managed keys. "By extending our platform to support Neon and Databricks, we're giving Postgres-native teams the tools to build real-time, AI-native architectures without rethinking their stack,' said Alok Pareek, co-founder and Executive Vice President of Engineering and Products at Striim. 'Our mission is to help customers modernize from legacy platforms and legacy ETL to real-time agent-incorporated intelligence—and Striim's Vector Agent and Neon CDC and delivery capabilities bring us one step closer to that future.' This expansion builds on Striim's momentum with Databricks, following the support for Databricks Delta Lake with open Delta table formats, and the launch of SQL2Fabric-X, which unlocks real-time SQL Server data for both Microsoft Fabric and Azure Databricks. With Neon now part of the Striim ecosystem, Postgres users can join this wave of modernization: streaming operational data to fuel AI and analytics without sacrificing performance or reliability. To learn more about Striim's support for Neon and Databricks, visit or contact our team at sales@ ABOUT STRIIM, INC. Striim pioneers real-time intelligence for AI by unifying data across clouds, applications, and databases via a fully managed, SaaS-based platform. Striim's platform, optimized for modern cloud data warehouses, transforms relational and unstructured data into AI-ready insights instantly with advanced analytics and ML frameworks, enabling swift business action. Striim leverages its expertise in real-time data integration, streaming analytics, and database replication, including industry-leading Oracle, PostgreSQL, MongoDB CDC technology, to achieve sub-second latency in processing over 100 billion daily events for ML analytics and proactive decision-making. To learn more, visit Media Contact: Dianna Spring, Vice President of Marketing at StriimPhone: (650) 241-0680 ext. 354Email: press@ Source: Striim, in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
